IN8bio Inc (INAB)
0.28
+0.01
(+2.64%)
USD |
NASDAQ |
Oct 31, 16:00
0.28
0.00 (0.00%)
After-Hours: 20:00
IN8bio Cash from Operations (TTM): -24.57M for June 30, 2024
Cash from Operations (TTM) Chart
Historical Cash from Operations (TTM) Data
| Date | Value |
|---|---|
| June 30, 2024 | -24.57M |
| March 31, 2024 | -23.82M |
| December 31, 2023 | -23.34M |
| September 30, 2023 | -26.44M |
| June 30, 2023 | -26.47M |
| March 31, 2023 | -27.00M |
| December 31, 2022 | -24.12M |
| September 30, 2022 | -18.35M |
| Date | Value |
|---|---|
| June 30, 2022 | -18.97M |
| March 31, 2022 | -15.56M |
| December 31, 2021 | -13.51M |
| September 30, 2021 | -13.06M |
| June 30, 2021 | -8.817M |
| March 31, 2021 | -8.017M |
| December 31, 2020 | -7.133M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (TTM) Range, Past 5 Years
-27.00M
Minimum
Mar 2023
-7.133M
Maximum
Dec 2020
-18.61M
Average
-18.97M
Median
Jun 2022
Cash from Operations (TTM) Benchmarks
| Genprex Inc | -20.79M |
| Ensysce Biosciences Inc | -9.783M |
| Biomarin Pharmaceutical Inc | 414.70M |
| Arbutus Biopharma Corp | -72.88M |
| GlycoMimetics Inc | -35.70M |